SYNOPSIS: Expansion of the metformin label to include patients with mild-to-moderate kidney disease is appropriate.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content